Protecting the "DUPHA" Dynasty: Why the Bombay High Court Struck Down a Deceptively Similar Pharmaceutical Mark to Preserve the Purity of the Register and Prevent Consumer Confusion.

🔒 For Members Only

Case: ABBOTT PRODUCTS OPERATIONS AG THROUGH TEJAL MUNDKAR v. Menschlich Healthcare OPC Private Limited
Court: Bombay High Court
Date: 15-06-2026
Law: Trade Marks Act.

Full Judgment → MCQ Test →

In the high-stakes world of pharmaceutical branding, a name is more than just a marketing tool; it is a vital safeguard for public health. A recent judgment by the Bombay High Court in the case of Abbott Product Operations AG v. Menschlich Healthcare (OPC) Private Limited has reinforced the stringent protections afforded to established "families" of medicinal trademarks. The ruling serves as a masterclass in the "purity of the register" and the heightened duty of care required when dealing with life-saving drugs.

The "Stricter Standard" for Pharmaceutical Marks

One of the most impactful takeaways from this judgment is the court's reaffirmation that pharmaceutical trademarks are held to a much higher standard of scrutiny than ordinary consumer goods. While a confusingly similar name for a snack might lead to a minor economic loss, a mistake in the pharmacy can be fatal. The court leaned heavily on the precedent set in the Cadila Healthcare case, noting that even the slightest probability of confusion in medicinal products requires judicial intervention.

"When a particular medicinal or a pharmaceutical product is involved as the impugned trade mark which may deceive the public or cause a confusion with respect to another trademark, it is the Court's primary duty to take utmost care to prevent any such possibility of confusion in the use of trademarks."

The Power of the "Family of Marks" Doctrine

The Petitioner, Abbott, successfully argued that their "DUPHA" prefix (derived from Dutch Pharmaceuticals) constituted a "family of marks", including well-known names like DUPHASTON and DUPHALAC. The court found that when a proprietor uses a consistent prefix across multiple products, that prefix becomes a "source identifier" in the mind of the consumer. Consequently, a competitor cannot simply tack on a new suffix—like "CHRIT"—and claim the mark is distinctive. The association with the established family is too strong to ignore.

Coined Terms vs. Common Language

The Respondent argued that "DUPHA" was common to the trade (publici juris). However, the court highlighted a critical distinction: "DUPHA" is a coined acronym, not a generic or descriptive term. Because it was an arbitrary creation, it deserved a higher degree of protection. The judgment reminds us that while "Apple" might be descriptive for fruit, it is arbitrary for electronics; similarly, "DUPHA" was found to be entirely arbitrary and distinctive in the context of dydrogesterone preparations.

Purity of the Register Trumps Procedural Delay

A surprising element for many practitioners is the court's stance on delay. The Respondent argued that Abbott had waited too long to challenge the registration. The court dismissed this, ruling that in rectification proceedings under Section 57 of the Trade Marks Act, the "purity of the register" is the paramount concern. If a mark is deceptively similar and poses a risk to public interest, the fact that the petitioner was slow to act does not validate a wrongful entry on the register.

"The primary duty of the Court is towards the public and the purity of the register. Duty of the Court must always be to protect the public irrespective of what hardship or inconvenience it may cause to a particular party whose trade mark is likely to deceive or cause confusion."

The High Burden of Proving "Common to Trade"

The Respondent attempted to show that many other companies used the "DUPHA" prefix by citing various entries in the Trademark Registry. The court's response was a stern reminder of evidentiary requirements: merely showing that a mark exists on paper (the register) is not enough. To prove a term is "common to the trade", a party must provide evidence of actual, substantial commercial use in the market. Without sales figures or advertisements from those third parties, registry search reports are insufficient to dilute a petitioner's rights.

Conclusion: A Victory for Consumer Safety

This judgment is a clear signal to the pharmaceutical industry that "riding on the coattails" of established brands through minor phonetic variations will not be tolerated. By prioritizing the "average man of ordinary intelligence" over the "specialized medicinal practitioner", the court ensures that trademark law continues to serve its most important function: preventing confusion where the stakes are literally a matter of life and death.